Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 14:13:1117-1131.
doi: 10.2147/DMSO.S213379. eCollection 2020.

Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges

Jonathan D Chevinsky  1 , Thomas A Wadden  2 , Ariana M Chao  2   3
Affiliations
Review

Binge Eating Disorder in Patients with Type 2 Diabetes: Diagnostic and Management Challenges

Jonathan D Chevinsky et al. Diabetes Metab Syndr Obes. .

Abstract

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of disordered eating behaviors including binge eating disorder (BED). Comorbid BED in patients with T2DM has been associated with adverse clinical outcomes such as higher body mass index (BMI) and depressive symptoms. Identifying and addressing this disorder in patients with T2DM is a significant challenge for health-care providers. The purpose of this narrative review is to discuss current perspectives on BED in the context of T2DM with implications for screening and management of these highly comorbid conditions. BED continues to be underrecognized and underdiagnosed. However, there are established tools that providers can use to screen for BED such as the SCOFF Questionnaire and Questionnaire on Eating and Weight Patterns-5. There are several effective treatments for BED including cognitive behavioral therapy, interpersonal therapy, and lisdexamfetamine dimesylate. However, few studies have examined the effects of these treatments in patients with co-morbid T2DM and BED.

Keywords: binge eating disorder; diabetes; eating disorders; obesity.

PubMed Disclaimer

Conflict of interest statement

Dr Thomas A Wadden reports personal fees from Novo Nordisk, Weight Watchers (WW), outside the submitted work. Dr Ariana M Chao reports grants, personal fees from Shire Pharmaceuticals, WW International., Inc., outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Centers for Disease Control. National Diabetes Statistics Report, 2017 Estimates of Diabetes and Its Burden in the United States Background.; 2017.
    1. Wielgosz A, Dai S, Walsh P, McCrea-Logie J, Celebican E. Comorbid conditions in canadians hospitalized because of diabetes. Can J Diabetes. 2018;42(1):106–111. doi:10.1016/j.jcjd.2017.03.004 - DOI - PubMed
    1. Cryer MJ, Horani T, DiPette DJ. Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens (Greenwich). 2016;18(2):95–100. doi:10.1111/jch.12638 - DOI - PMC - PubMed
    1. Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17:1. doi:10.1186/s12916-019-1373-y - DOI - PMC - PubMed
    1. Bralić Lang V, Bergman Marković B. Prevalence of comorbidity in primary care patients with type 2 diabetes and its association with elevated HbA1c: a cross-sectional study in Croatia. Scand J Prim Health Care. 2016;34(1):66–72. doi:10.3109/02813432.2015.1132886 - DOI - PMC - PubMed